An observational study in HIV Infections and Antiretroviral Agents, sponsored by University Hospital, Bordeaux. Active, not recruiting at 19 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-07.
Sponsored by University Hospital, Bordeaux · Observational
HIV infection is now a chronic disease in countries where antiretroviral treatments (ART) are largely available. Long-term follow-up is required to describe and understand the evolution of morbidities and complications as well as new treatments side effects.
The main objective of the cohort is to describe and study the evolution of HIV infection in ART-treated individuals.
The survival of people living with HIV (PLHIV) taking antiretroviral therapy (ART) is now close to what is reported in the general population in northern countries. However, PLHIV experience an increased risk of morbidities that the ANRS CO3 Aquitaine Cohort has largely contributed to describe in the last years. Among contributing factors to this excess of morbidity, immune suppression, immune activation, and exposition to cardiovascular and cancer risk factors as well as ageing represent possible intervention targets. Long-term follow-up is required to describe and understand the evolution of morbidities and complications as well as ART side effects.
Moreover, the global evaluation of health in PLHIV, including psychiatric, neurologic and social determinants and not only biomedical determinants represents one of the public health challenges of the next decade in the field of HIV infection.
The aim of the present study is to study the emerging morbidity occurring during the course of HIV infection in people treated with ART as well as to describe the tolerance and efficacy of new available ART regimens.
The follow-up of patients will be performed according to national guidelines. Demographic, clinical, biological and therapeutic data will be captured at each patient's hospital contact according to a standardized questionnaire.
All events occurring during the course of clinical management will be prospectively registered in the database according to the ICD 10th revision. A biobank will be collected from every consenting PLHIV at inclusion in the cohort and then every two years.
Patients infected with HIV-1 (PLHIV)
Exclusion Criteria:
7500 patients infected with HIV-1
Socio-demographic characteristics of people living with the HIV
Time frame: Each 12 months from baseline for 4 years (M48)
HIV infection characteristics of people living with the HIV
group of infection, stage of infection, duration since first serology positive, CD4 nadir, last CD4 measurement, CD4 / CD8 ratio
Time frame: Each 12 months from baseline for 4 years (M48)
comorbidities of people living with the HIV
Time frame: Each 12 months from baseline for 4 years (M48)
co-infections of people living with the HIV
Hepatitis B, Hepatitis C, cytomegalovirus infection...
Time frame: Each 12 months from baseline for 4 years (M48)
Therapeutics description
naïve / treated status, dosage
Time frame: Each 12 months from baseline for 4 years (M48)
virological responses
Time frame: Each 12 months from baseline for 4 years (M48)
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Bordeaux